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Abstract
Background: In clinical trials, the opportunity for an early stop during an interim analysis (either for efficacy or for
futility) may relevantly save time and financial resources. This is especially important, if the planning assumptions
required for power calculation are based on a low level of evidence. For example, when including two primary
endpoints in the confirmatory analysis, the power of the trial depends on the effects of both endpoints and on their
correlation. Assessing the feasibility of such a trial is therefore difficult, as the number of parameter assumptions to be
correctly specified is large. For this reason, so-called ‘group sequential designs’ are of particular importance in this
setting. Whereas the choice of adequate boundaries to stop a trial early for efficacy has been broadly discussed in the
literature, the choice of optimal futility boundaries has not been investigated so far, although this may have serious
consequences with respect to performance characteristics.
Methods: In this work, we propose a general method to construct ‘optimal’ futility boundaries according to
predefined criteria. Further, we present three different group sequential designs for two endpoints applying these
futility boundaries. Our methods are illustrated by a real clinical trial example and by Monte-Carlo simulations.
Results: By construction, the provided method of choosing futility boundaries maximizes the probability to correctly
stop in case of small or opposite effects while limiting the power loss and the probability of stopping the study
‘wrongly’. Our results clearly demonstrate the benefit of using such ‘optimal’ futility boundaries, especially compared
to futility boundaries commonly applied in practice.
Conclusions: As the properties of futility boundaries are often not considered in practice and unfavorably chosen
futility boundaries may imply bad properties of the study design, we recommend assessing the performance of these
boundaries according to the criteria proposed in here.
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Background
In recent years, the flexibility and efficiency of clinical
trials became increasingly important, in particular for tri-
als from the pharmaceutical industry. Group sequential
designs give the opportunity to stop the study early dur-
ing an interim analysis, thereby saving time and financial
resources. Generally, the study can either be stopped for
efficacy if the study goal is prematurely achieved or for
futility, if reaching the aim of the trial seems desper-
ate. Decision rules to stop a trial early for efficacy have
been broadly investigated. Since the pioneering works of
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Pocock [1] and O’Brien and Fleming [2], these designs
have been implemented since long in clinical trial rou-
tine. A comprehensive overview and general concepts of
the statistical methodology in group sequential designs
are provided by Jennison and Turnbull [3]. With respect
to futility stopping, there are mainly two fundamental
approaches in the statistical literature [3, 4]. The first
approach is a conditional one, where the study is stopped
for futility, if the conditional power falls under a prespec-
ified threshold. This conditional approach can further be
divided into stochastic curtailment [5, 6], a frequentist
approach, and methods based on the predictive power
or the predictive probability [4], which are partially or
fully Bayesian methods [7, 8]. The second approach is to
define futility stopping boundaries either in isolation or
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in conjunction with group sequential efficacy boundaries
[3]. The choice of adequate boundaries to stop the study
early for futility has been discussed only briefly in these
works. This is astonishing as unfavorable futility bound-
aries may have serious consequences with respect to the
performance of the study design.
In our work, we propose a general method for the con-
struction of futility boundaries. In addition, we introduce
several intuitive criteria which should be considered when
defining ‘optimal’ futility boundaries described as follows.
First, unless offset by increased sample size, early stopping
for futility reduces the overall power. The aim is thus to
avoid a too high loss in power. Second, the study should
be stopped early for futility if the unknown true effect is
far away from the anticipated effect under the alternative
hypothesis (‘correctly’ stopping for futility). Finally, if the
unknown true effect corresponds to the anticipated effect
under the alternative hypothesis, the study should not be
stopped for futility (‘wrongly’ stopping for futility).
In principle, these optimality criteria might be applied
in any two-stage design. In the literature, group sequen-
tial designs with futility stopping are usually formulated
for a single primary endpoint [9–12]. Beside several works
on interim efficacy evaluation in group sequential designs
with multiple endpoints [13–18] there are only few works
suggesting group sequential methods for multiple end-
points including futility stopping [19, 20]. However, we
believe that such designs are of particular relevance for
clinical trials with multiple primary endpoints for the rea-
son specified in the following. When considering two
endpoints, the power of the trial depends on the expected
effects of both endpoints and on the correlation between
them. Assessing the feasibility of the trial is therefore a
particular challenge, as the number of required parame-
ter values to be correctly specified in the planning stage
is large. Therefore, the option for an early futility stop is
attractive to account for these uncertainties. Moreover,
the required sample size for a clinical trial with several pri-
mary endpoints is usually higher than for a single primary
endpoint and therefore the need to stop the trial early in
case of unfavorable outcomes is of particular importance.
In this work, we apply the general construction method
of futility boundaries to three different two-stage group
sequential designs for two endpoints. For these designs,
we propose an algorithm to choose ‘optimal’ futility
boundaries with respect to the above mentioned criteria.
Thereby as Jennison and Turnbull [3], we define group
sequential futility stopping boundaries in conjunction
with efficacy boundaries.
This paper is organized as follows. The “Methods”
section introduces first the study design, the test prob-
lem and general principles of group sequential designs
and then describes the new approach of choosing ‘opti-
mal’ futility stopping boundaries as motivated above.
Moreover, different group sequential designs for two end-
points profiting from these optimal futility boundaries are
proposed. Furthermore, the derivation of ‘optimal’ futility
boundaries is described. The “Results” section investigates
the performance characteristics of the new methods by
means of Monte-Carlo simulations cased on a real clinical
trial example. Finally, we conclude with a discussion.
Methods
Standard group sequential methods allow stopping a study
early at an interim analysis where the outcome is observed
and analyzed for a part of the maximum number of
patients. The study can thereby either be stopped for
efficacy or for futility. For simplicity, we restrict our con-
siderations to a controlled clinical trial with one interim
analysis and one final analysis resulting in a group sequen-
tial design with two stages. In this section, we first con-
sider the situation of a single endpoint in order to describe
the new approach of choosing futility boundaries gener-
ally. After that, group sequential designs for two endpoints
are proposed.
Test problem and general principles
The (local) test problem for the endpoint under investiga-
tion is given by
Hδ0 : θ ≤ δ versus Hδ1 : θ > δ, δ ≤ 0, (1)
where δ = 0 implies a one-sided superiority test prob-
lem and δ < 0 corresponds to a test for non-inferiority.
Considering binary or continuous outcome measures, θ
is given by the absolute risk difference or mean dif-
ference, respectively, whereas for time-to-event data θ
indicates the logarithm of the hazard ratio. The stan-
dard approaches to test for superiority are given by the
chi-square test for binary data, the t-test for continuous
data and the log-rank test for time-to-event data [21].
Note that all these test statistics are approximately stan-
dard normally distributed under the corresponding null
hypothesis.
In a two-stage group sequential design the test statis-
tics T1 and T2 used at the interim analysis and at the
final analysis, respectively, corresponds to the standard
test statistics of a fixed design using all data collected
so far with some modifications for the case of time-to-
event data [22]. The correlation between the normally dis-
tributed test statistics T1 and T2 then exclusively depends
on the (assumed) information fraction at interim which
can be specified in the planning stage. After the correla-
tion between the test statistics has been determined, the
adjusted (one-sided) local significance levels α1 and α2 can
be defined by taking this correlation into account. The
local significance levels in a group sequential design can
be chosen in various ways, e.g. as constant or increasing
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in time [1, 2, 23–25]. Then the null hypothesis given in
(1) is rejected at interim whenever the one-sided p-value
p1 referring to T1 fulfills p1 ≤ α1. The null hypothesis
is rejected at the final analysis whenever the one-sided
p-value p2 corresponding to T2 fulfills p2 ≤ α2.
In general, stopping for futility without compromising
the type I error is possible at any time and indepen-
dent of any predefined rules as an early acceptance of H0
decreases the actual type I error rate. In the context of
group sequential designs, it can generally be differentiated
between binding and non-binding stopping for futility
rules, compare also Bretz et al [26]. ‘Binding’ means that
stopping for futility at the interim analysis is obligatory
whenever the futility criteria are met. When the data sug-
gest stopping for futility, it is thus not allowed to continue
the trial for other external reasons. If a binding futility rule
is applied, the local significance levels can be increased in
order to fully exhaust the global significance level which
is otherwise no longer guaranteed as futility stopping
implies a lower probability of rejecting the null hypothe-
sis. In contrast, the non-binding version does not commit
early futility stopping. Therefore, there may be situations
were the data advise stopping for futility, but the study is
continued nonetheless for other reasons, e.g. as new exter-
nal information suggests that the futility criteria might be
too strong. As a consequence, the local significance levels
cannot be adjusted and the global significance level is not
fully exhausted. In clinical trial applications non-binding
futility boundaries are usually applied because they allow
reacting flexibly to interim results such as adverse events
or new external information. However, quantifying the
performance properties (in terms of power loss or ‘cor-
rectly’ and ‘wrongly’ stopping for futility) of non-binding
rules is impossible as the study progress is not predictable
from the observed effect at interim.
For the reasons specified above, we will focus in this
work on binding stopping criteria at interim but without
increasing the local significance levels. In general, a futil-
ity rule can equivalently be expressed either in terms of
a boundary for the test statistic or as an upper bound for
the p-value.We will use the latter approach without loss of
generality, that is the study is stopped for futility at interim
whenever p1 > αf , where αf is the futility boundary.
Defining optimal binding futility boundaries
Choosing adequate futility boundaries is an important
challenge as unfavorable futility boundariesmay have seri-
ous consequences with respect to the performance of the
study design. In case of ‘strong’ futility boundaries, for
example, if the study is stopped for futility whenever the
one-sided p-value is larger than 0.2, the overall power loss
can be large and the study might be stopped for futility in
too many situations caused by only small but non-relevant
deviations from the planning assumptions. In such cases,
the probability of ‘wrongly’ stopping for futility is high.
In the case of ‘liberal’ futility boundaries, given, for exam-
ple, as a lower bound for the p-value of 0.8, the overall
power loss is quite small but at the same time small or
opposite effects often do not result in an early stop for
futility. Hence, the probability of ‘correctly’ stopping for
futility is low in this case [9]. The idea of ‘optimal’ futil-
ity boundaries proposed here is to provide a high rate
of ‘correctly’ stopping for futility and to simultaneously
restrict the loss in power and the rate of ‘wrongly’ stopping
for futility. To provide ‘optimal’ futility boundaries in this
sense, an ‘admissibility condition’ is defined as follows.
Definition 1 (βγ -admissible futility boundaries) Let
Hδ0 : θ ≤ δ denote the one-sided null hypothesis of the
corresponding test problem and Hδ1,θ1 be the alternative
hypothesis for a given effect θ1 > δ, for which the trial
should have power 1 − β ∈[ 0, 1] given an overall signif-
icance level of α. Let βl ∈[ 0, 1] be the acceptable overall
power loss in a group sequential design with a binding stop-
ping for futility rule and let γ ∈[ 0, 1] denote the acceptable
probability of stopping for futility under Hδ1,θ1 , the so called
‘wrongly’ stopping for futility rate. Then a futility bound-
ary αf is called βγ -admissible if the following conditions
are met:
1. PHδ1,θ1 (H
δ
0 is rejected in stage 1) +
PHδ1,θ1 (H
δ
0 is rejected in stage 2 and Hδ0 is neither rejected
nor accepted in stage 1) ≥ 1 − β − βl ,
2. PHδ1,θ1 (The study is stopped for futility based on αf in stage
1) ≤ γ ,
where PHδ1,θ1 (·) denotes the probability under the assump-
tion that Hδ1,θ1 holds true.
For predefined values of βl and γ there generally exist
several βγ -admissible futility boundaries. These bound-
aries differ in the probability of ‘correctly’ stopping for
futility as there is no condition on exhausting the admis-
sible power loss βl or the probability of ‘wrongly’ stopping
for futility γ .
In order to determine ‘optimal’ futility boundaries, the
probability of early stopping for futility should be prefer-
ably high in case of a small or opposite effect which devi-
ates considerably from the anticipated treatment effect θ1.
This motivates the following definition.
Definition 2 (βγ -optimal futility boundaries) Let Hδ0 :
θ ≤ δ denote the one-sided null hypothesis of the corre-
sponding test problem and Hδ1,θ1 be the alternative hypoth-
esis for a given effect θ1 > δ, for which the trial should
have power 1 − β ∈[ 0, 1] given an overall significance
level of α. Let Aβl ,γ denote the set of all βγ -admissible
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futility boundaries for a maximally admissible power loss
βl ∈ [0, 1] and a maximally admissible ‘wrongly’ stopping
for futility rate γ ∈ [0, 1]. Let θ∗ < θ1 denote the largest
effect under Hδ1 for which stopping the study for futility
would still be considered as ‘correct’ and let Hδ1,θ∗ denote
the corresponding alternative hypothesis. Then the futility
boundary αf ∈ Aβl ,γ which maximizes the probability of
stopping for futility under Hδ1,θ∗ given as
αopt = max{
αf ∈Aβl ,γ
}
PHδ1,θ∗ (The study is stopped for futility based on αf in stage1)
is called βγ -optimal, where PHδ1,θ∗ (·) denotes the probabil-
ity under the assumption that Hδ1,θ∗ holds true.
The βγ -optimal futility boundary defines a lower bound
for the βγ -admissible boundaries, as all boundaries that
are larger than the βγ -optimal boundary automatically
meet the βγ -admissible conditions. Note that for group
sequential designs for a single endpoint (as well as for
designs with two endpoints we consider in this work) the
optimal futility boundary could also be determined by
maximizing the probability of correctly stopping under
the null hypothesis effect θ instead of under θ∗. How-
ever, in more complex multiple endpoint group sequential
designs this monotonicity property might no longer hold
true. The derivation of βγ -optimal futility boundaries will
be described below in “Derivation of the local significance
levels and βγ -optimal futility boundaries” section.
In general, the optimality of group sequential designs
is usually assessed by means of the average sample size,
where a low average sample size is preferable. Although
the average sample size is a common criteria to judge
the performance of a group sequential design, it has also
major shortcomings when applied as the unique mea-
sure of performance. For example, the power loss of a
group sequential design compared to a correctly speci-
fied single-stage design is a further performance criterion.
Liu et al. proposed a performance score combining both
criteria (average sample size and power loss) [27]. The
application of the performance score for the situation
of an intersection-union test is, e.g., provided by Kieser
et al. [28]. Despite these important new aspects discussed
in literature, there further remain some open topics with
respect to a performance assessment of a group sequen-
tial design: The average sample size is a summary measure
which does not necessarily show the true sample sizes
because the variability of the sample size is completely
ignored. Therefore, a low average sample size is only a
good optimality criteria if the variability of the sample
size is also low. Instead of looking at the average sample
size and its variability, an alternative approach could be
to judge the correctness of early stopping (implying a low
sample size) or continuing (implying a high sample size).
The latter is what we have investigated in our work.
Investigated group sequential designs with futility stop
based on two endpoints
Motivated by the fact that the application of adequate
binding futility boundaries is of particular interest when
analyzing several endpoints, we consider three different
group sequential designs that incorporate two endpoints
and different futility stopping rules. The aim is to define
a test procedure which offers a maximal gain in informa-
tion from two endpoints of interest but simultaneously
requires a minimal number of patients to save resources,
especially when the effects are lower than originally antic-
ipated. These specific two-stage designs will subsequently
be used to illustrate the impact of βγ -optimal futility
boundaries. In the following, the indexes EP1 and EP2
will denote the affiliation to the two endpoints under
investigation.
For Approaches 1 and 2, the aim is to show a signifi-
cant effect in both endpoints which are then commonly
referred to co-primary endpoints. In this case, the test
hypotheses can be formulated using the intersection-
union test principle
HIUT ,δ1,δ20 : H
EP1,δ1
0 ∪ HEP2,δ20 versus (2)
HIUT ,δ1,δ21 : H
EP1,δ1
1 ∩ HEP2,δ21 , δ1, δ2 ≤ 0, (3)
where the local test hypotheses are given as stated
in (1). The most rigorous requirement for a clinical
trial with two primary endpoints is to base the effi-
cacy proof on demonstrating superiority for both equiv-
alently relevant endpoints (HIUT ,0,00 versus H
IUT ,0,0
1 ).
In the case that the endpoints are of different rel-
evance, e.g. an efficacy and a safety endpoint, a
less rigorous test procedure may also be appropriate.
Therefore, Approach 2 combines a superiority test for
the efficacy endpoint with a non-inferiority test for the
safety endpoint or the endpoint of less clinical relevance
(HIUT ,0,δ20 versus H
IUT ,0,δ2
1 , δ2 < 0). Note that for the ease
of representation, it is assumed without loss of general-
ity that the efficacy endpoint corresponds to EP1. A group
sequential test procedure including binding futility stop-
ping rules for HIUT ,0,00 or H
IUT ,0,δ2
0 , respectively, is defined
as follows.
Approach 1 (HIUT ,0,00 ) and Approach 2
(HIUT ,0,δ20 , δ2 < 0)
Stage 1: • The study is stopped early with
rejection of HIUT ,δ1,δ20 if p
EP1
1 ≤ αEP11
and pEP21 ≤ αEP21 .
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• The study is stopped early for futility
(with acceptance of HIUT ,δ1,δ20 ) if
pEP11 ≥ αEP1f or pEP21 ≥ αEP2f .
Stage 2: At the final analysis, HIUT ,δ1,δ20 is rejected if
pEP12 ≤ αEP12 and pEP22 ≤ αEP22 . Otherwise
HIUT ,δ1,δ20 is accepted.
When an efficacy and a safety endpoint are considered
it is not necessarily required to perform a hypothesis test
for the safety endpoint. But even in this case, the option
to stop for futility can be based on both endpoints so that
small or opposite effects in the safety endpoint can addi-
tionally be ruled out. Approach 3 therefore considers a
situation were one endpoint is formally tested for superi-
ority at interim and at the final analysis and the other is
solely used as an additional criterion for futility stopping.
Thus, while the efficacy assessment is exclusively based on
endpoint 1, stopping for futility at interim can be based on
endpoint 1 or on endpoint 2. A further situation to apply
Approach 3 could be when a short-term surrogate is used
to assess the futility of the trial and a long-term efficacy
endpoint is used to assess the efficacy at the final analy-
sis. For example, in oncology trials a common surrogate
for overall survival is given by progression-free survival
which provides more events in a shorter observational
time-frame. The test problem is then given by
HEP1,00 : θ ≤ 0 versus HEP1,01 : θ > 0, (4)
which corresponds to the definition given in (1) with δ = 0
and the related group sequential procedure is defined as
follows.
Approach 3 (HEP1,00 )
Stage 1: • The study is stopped early with
rejection of HEP1,00 if p
EP1
1 ≤ αEP11 .• The study is stopped early for futility if
pEP11 ≥ αEP1f or pEP21 ≥ αEP2f .
Stage 2: At the final analysis, HEP1,00 is rejected if
pEP12 ≤ αEP12 . Otherwise HEP1,00 is accepted.
Unlike for the Approaches 1 and 2, the efficacy proof
is now only based on EP1. However, the other endpoint
EP2 still influences the study result, as early stopping for
futility due to EP2 is possible.
Derivation of the local significance levels and βγ -optimal
futility boundaries
As motivated above, we do not increase the local sig-
nificance levels to fully exhaust the type I error. There-
fore, the local levels can be chosen as usual in group
sequential designs without taking futility stopping into
account, e.g. constant or increasing [1, 2]. The derivation
of increased local significance levels in conjunction with
futility stopping (in order to exhaust the overal signifi-
cance level) is described in the Supplementary Material
(see Additional file 1).
To calculate the βγ -optimal futility boundaries for a
specific study situation, we implemented a search algo-
rithm in R which at first determines all constellations of
futility boundaries for both endpoints which simultane-
ously maximally exhaust the prespecified thresholds for
the probability of ‘wrongly’ stopping for futility γ and for
the power loss βl. Note that these are the βγ -admissible
boundaries. Subsequently the constellations of boundaries
which maximize the probability of ‘correctly’ stopping
for futility are determined, which are the βγ -optimal
boundaries.
Results
To illustrate application of the proposed methods, the
three group sequential designs incorporating two end-
points are applied (by simulations) to a real clinical
trial example. For these three designs, βγ -admissible
and βγ -optimal futility boundaries are calculated and
furthermore investigated in terms of overall power and
probability of ‘correctly’ and ‘wrongly’ stopping for futility.
Clinical trial example and simulation design
The RENAAL study was a randomized, double-blind,
placebo-controlled trial conducted to investigate the
effect of losartan on renal and cardiovascular outcomes
in patients with type 2 diabetes and nephropathy [29].
The primary outcome was a time-to-first event compos-
ite endpoint, where the events correspond to doubling the
baseline serum creatinin concentration, end-stage renal
disease, and death. The recruitment time was fixed to 2
years and the minimal follow-up duration to 3.5 years.
Patients were allocated to the placebo and the interven-
tion group in a 1 : 1 ratio. The original planning assump-
tions used for sample size calculation were given by
estimated 5 year event rates of 0.58 and 0.464 in the
placebo and the intervention group, respectively [30].
Assuming constant hazard functions over time (exponen-
tially distributed survival times), the underlying hazards
can be directly calculated from the given event rates
[31]. The resulting hazard ratio for the composite end-
point is given by λCCE/λICE = 0.0145/0.0104 = 1.394,
wherethe parameter λ denotes the hazard function, which
is assumed to be constant here, the index CE stands for
‘composite endpoint’ and the group affiliation is expressed
by the indexes I and C for the intervention and the control
group, respectively.
The clinically most relevant component of the com-
posite endpoint defined above is clearly given by death.
Within the context of a composite endpoint, current
guidelines on clinical trials systematically recommend
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to investigate the components of a composite endpoint
separately, in particular the most relevant components
[32–34]. Therefore, it might provide a relevant gain in
information to include this endpoint in the analysis strat-
egy instead of exclusively considering the composite end-
point. The two endpoints under consideration are thus
given by a composite endpoint combining doubling of
baseline serum creatinin concentration, end-stage renal
disease, and death and by the endpoint death alone.
Thus, whenever a death occurs, this corresponds to an
event in both endpoints. However, the composite end-
point consist of more events of other types. This illustrates
that the two endpoints are correlated by construction.
The assumed event rates for the endpoint death have
not been published. For the sake of illustration, we
assume a hazard ratio for death given by λCMC/λIMC =
0.01/0.0074 = 1.351, where the index MC stands for
‘main component’.
The presented example is appealing in the sense that
the two endpoints correspond to a composite endpoint
and a main component. In the specific case of a compos-
ite endpoint, any additional confirmatory information on
the components provides an important gain in informa-
tion. Therefore, application of all three group sequential
approaches presented in this manuscript can be illustrated
by means of a unique example. In most other clinical trial
applications only one of the proposed test problems fits
the specific confirmatory requirements.
‘Correctly’ and ‘wrongly’ stopping for futility
In order to differentiate between ‘correctly’ and ‘wrongly’
stopping for futility, we modify the underlying hazard
assumptions. Consequently, we consider different haz-
ard ratios for the main component that deviate from
the original planning assumption given by λCMC/λIMC =
0.01/0.0074 = 1.351. Of course, deviations from the
planning assumptions could also occur in the composite
endpoint or in both endpoints. As every event in the main
component also corresponds to an event in the composite
endpoint and for sake of an easier illustration, we restrict
our considerations to deviations in the main component.
The following 7 hazard ratio scenarios for the main com-
ponent are considered {1.351; 1.3; 1.25; 1.2; 1.15; 1.1; 1.05},
where without loss of generality the hazard in the inter-
vention group was fixed to λIMC = 0.0074 and devia-
tions in the hazard ratio are due to variations from the
assumptions for λCMC . Scenario 1 corresponds to the orig-
inal planning assumptions for the main component while
the remaining Scenarios 2 to 7 correspond to decreasing
treatment effects in the main component. To determine
βγ -optimal futility boundaries according to Definition 2,
the largest effect under the alternative hypothesis has to
be determined for which stopping the study for futil-
ity would still be considered as ‘correct’. In the RENAAL
study, a hazard ratio of λCMC/λIMC = 1.2 might be a rea-
sonable choice for the main component. Consequently,
mis-specifications of the hazard ratio given in Scenarios 2
and 3 might be acceptable, whereas for Scenario 4 to 7 it
would be justified to stop the study early for futility. This
threshold should be based on aspects of clinical relevance
and should be discussed with clinical experts. Note that
we base for sake of simplicity the threshold for ‘correctly’
stopping for futility in this example only on deviations
from the planning assumptions in the main component.
This threshold can also depend on the composite end-
point or even on both endpoints.
Sample size considerations
On the way to determine βγ -optimal futility boundaries
and especially to assess the overall power loss βl, at first
the reference group sequential design without stopping
for futility has to be fixed. For this illustrating example,
we apply a two-stage group sequential design where the
interim analysis is performed after an anticipated infor-
mation fraction of 0.5 and where the local significance
levels are adjusted according to Pocock [1]. Moreover, we
assume that patient recruitment is stopped during the
interim analysis. All these settings could be chosen differ-
ently and are only of illustrative purpose here. We assume
a target power of β = 0.90 and an overall one-sided signif-
icance level of α = 0.025 for the reference design without
stopping for futility. The required sample sizes for these
reference designs are then given by 1260 (630 per group)
for Approach 1 and by 820 (420 per group) for the less
stringent Approach 2 where the main component is tested
for non-inferiority with a non-inferiority margin of 0.9
in terms of the hazard ratio. The correlation of the test
statistics are then given by r1 = 0.83 and r2 = 0.82 for
Approach 1 and Approach 2, respectively. For Approach
3, testing exclusively the composite endpoint yields a sam-
ple size of 730 (365 per group). An analytical derivation
of the required sample sizes and the correlations between
the test statistics is difficult and the results are thus
based on simulations. More details on the sample size
derivations are described in the Supplementary Material
(see Additional file 2).
Simulation results
For each scenario described above, we simulated 10.000
data sets and applied the corresponding group-sequential
designs. From these, rates of overall power and probability
of wrongly or correctly stopping for futility, respectively,
are estimated for different constellations of stopping for
futility boundaries. The power loss is given as the antici-
pated power minus the observed overall power. The rates
of early stopping in Scenario 1 (according to the plan-
ning assumptions) or Scenario 4 lead to the probability
of wrongly or correctly stopping for futility, respectively.
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For varying constellations of futility boundaries the cor-
responding values of overall power and probability of
stopping for futility differ consequentially. A search algo-
rithm (compare “Defining optimal binding futility bound-
aries” section) finally chooses the constellation of futility
boundaries yielding an acceptable power loss while min-
imizing wrongly stopping for futility. This algorithm can
be obtained from the authors on request.
Optimal to non-optimal futility boundaries
In order to calculate the βγ -admissible and βγ -optimal
futility boundaries the maximal acceptable power loss
with stopping for futility is set to βl = 0.05 and the
admissible ‘wrongly’ stopping for futility rate is chosen as
γ = 0.025.
For Approach 1, futility bounds given by αCEf = 0.43 and
αMCf = 0.44 maximize the ‘correctly’ stopping for futil-
ity rate at 0.117. In Approach 2, the βγ -optimal futility
boundaries are given by αCEf = 0.65 and αMCf = 0.37 with
a probability of ‘correctly’ stopping for futility of 0.087.
Approach 3 yields βγ -optimal boundaries of αCEf = 0.69
and αMCf = 0.65 with a probability of ‘correctly’ stopping
for futility of 0.085.
Comparison of design performance between optimal and
non-optimal futility boundaries
As a reference, we compare the βγ -optimal futility
bounds with a common futility boundary of αCEf =
αMCf = 0.5 which is often applied in practice. For
Approach 1 and Approach 2 this choice is more liberal
than the βγ -optimal boundaries. Therefore, the probabil-
ity of ‘correctly’ stopping for futility is smaller with 0.09 <
0.117 for Approach 1 and 0.047 < 0.087 for Approach 2.
Neither the probability of ‘wrongly’ stopping for futility
(given as 0.016 for Approach 1 and 0.018 for Approach 2)
nor the overall power loss (given as 0.017 for Approach 1
and 0.006 for Approach 2) exhaust the maximal admissi-
ble values γ = 0.025 and βl = 0.05. However, a common
futility bound of 0.5 is contained in the set of admissi-
ble boundaries for the first two approaches. For Approach
3 the reference futility boundaries correspond to stricter
values than the βγ -optimal ones. Therefore, the probabil-
ity of ‘correctly’ stopping for futility is higher with 0.158 >
0.085 but to the prize of a higher probability of ‘wrongly’
stopping for futility with 0.06 which exceeds the admissi-
ble value γ = 0.025 considerably. At the other hand the
overall power loss of 0.04 does not exhaust the maximal
admissible value βl = 0.05.
Impact of the planning assumptions on power loss and
probability of stopping for futility
For Approach 1, Fig. 1 illustrates the dependency of the
probability of stopping for futility (left plot) and the corre-
sponding overall power (right plot) as function of sample
size per group for the different hazard ratio scenarios
of the main component given above for the βγ -optimal
futility boundaries defined above. The differently colored
Fig. 1 Probability of stopping for futility (left figure) and overall power (right figure) for Approach 1 using the futility βγ -boundaries αCEf = 0.43 and
αMCf = 0.44 for composite endpoint and main component, respectively. The vertical dotted line shows the sample size required to achieve a power
of 0.9 for the reference design without futility stopping. Horizontal dotted lines indicate the thresholds for the rate of ’wrongly’ stopping for futility
(left figure) and for the admissible power loss (right figure), respectively
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lines in Fig. 1 match the seven hazard ratio scenarios,
where the black line corresponds to the original planning
assumption.
The right plot shows the overall power where for the
βγ -optimal futility boundaries the line of the original
assumption (black line) should not fall below the admissi-
ble power 1 − β − βl = 0.90 − 0.05 = 0.85 (horizontal
dotted line) for a sample size of 630. Decreasing the
sample size or decreasing the hazard ratio (which corre-
sponds to a larger deviation from the original planning
assumptions) results in a monotone loss in overall power.
Note that the global power depends on the correlation
of the two test statistics. If the correlation is unknown
in the planning stage, we recommend investigating the
power by simulation. In general, the power increases with
increasing absolute value of the correlation.
The left plot of Fig. 1 displays the probability of stopping
for futility. In case of the original planning assumption
(black line), the probability of ‘wrongly’ stopping for futil-
ity is given by 0.025 for ngroup = 630. As a hazard ratio
of 1.2 was considered as the largest effect under the alter-
native hypothesis for which stopping the study for futility
would still be considered as correct, the probability of ‘cor-
rectly’ stopping for futility is given by 0.117. Decreasing
the sample size or decreasing the hazard ratio (which cor-
responds to a larger deviation from the original planning
assumptions) results in a monotone increase of the prob-
ability of stopping for futility. Note that for decreasing
probability of ‘wrongly’ stopping for futility the probability
of ‘correctly’ stopping for futility also decreases.
For Approach 2, the corresponding plots look simi-
lar, but additionally the non-inferiority margin of the
main component mainly influences the required sam-
ple size. For Approach 3, the displayed curves are much
closer to each other, which means that on the one
hand the loss in power is less prominent but on the
other hand the probabilities of ‘correctly’ stopping for
futility are also smaller. Figures for Approach 2 and
Approach 3 are provided as Supplementary Material
(see Additional files 3 and 4).
Influence of the choice of futility boundaries on power and
probability of stopping - Admissible and optimal futility
boundaries
Figure 2 shows the constellations of futility boundaries
which meet the admissible condition (Definition 1) for
Approach 1 (left plot), Approach 2 (middle plot), and
Approach 3 (right plot). As for larger futility bound-
aries the overall power increases and the probability of
‘wrongly’ stopping for futility decreases, all boundary
constellations right hand from the curves also fulfill the
admissible condition. However, the probability of ‘cor-
rectly’ stopping for futility also decreases with increasing
futility boundaries. The βγ -optimal pair of futility bound-
aries for the composite endpoint and the main component
must be an element of the plotted curve, but not all ele-
ments of the curve are βγ -optimal. Colors from yellow
to green show increasing probabilities of ‘correctly’ stop-
ping for futility. In all three approaches, the left- hand side
of the curves show higher probabilities of ‘correctly’ stop-
ping for futility, whereas for increasing futility boundaries
in the main component this probability decreases.
Approach 3 shows the largest futility boundaries as
the efficacy proof is based only on the composite end-
point and the overall power loss is thus most vulnerable
to decreasing futility boundaries. Comparing the βγ -
optimal futility boundaries of the first two approaches,
Approach 2 shows a larger value for the composite end-
point but a smaller for the main component. This is
due to the fact that basing the efficacy proof on a non-
inferiority test of the main component but on superiority
for the composite assigns a higher impact to the composite
Fig. 2 Lower bounds for βγ -admissible futility boundaries (yellow, orange and red dots) and βγ -optimal futility boundaries (green dot with
coordinates as indicated by the dotted lines) for the composite endpoint and the main component for Approach 1 (left plot), Approach 2 (middle
plot), and Approach 3 (right plot)
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endpoint. Consequently, the overall power loss is more
vulnerable to a decreasing futility boundary in the com-
posite endpoint. For the specific clinical trial situation at
hand, all approaches show medium and similar ‘correctly’
stopping for futility rates but Approach 1 by far requires
the largest sample size. Approach 2 clearly provides more
gain in information compared to Approach 3 as both end-
points are included in the efficacy claim. For this reason,
Approach 2 should be recommended here.
Discussion
By construction, the provided method of choosing futility
boundaries maximizes the probability of detecting small
or opposite effects while limiting the power loss and
the probability of stopping the study ‘wrongly’. The sim-
ulation results provided in “Simulation results” section
clearly demonstrate the benefit of using such ‘optimal’
futility boundaries in the considered scenarios, especially
compared to a futility bound of αf = 0.5 which is
commonly applied in practice. However, these criteria
are generally applicable to any type of group sequential
designs. In order to determine the most suitable two-
stage design out of the three approaches presented in
“Investigated group sequential designs with futility stop
based on two endpoints” section, we recommend to com-
pare the performance properties of the designs under
βγ -optimal futility boundaries, which usually differenti-
ate between the designs. The design is then chosen by
considering the specific study situation, the gain in infor-
mation provided by the design, and the probability of ‘cor-
rectly’ stopping for futility under the βγ -optimal futility
boundaries.
In this work we investigated binding futility bound-
aries in order to quantify the performance properties of
the corresponding group sequential designs. However, the
resulting performance properties of a binding rule can
also be used to approximate the performance proper-
ties of more liberal non-binding rules as some deviations
from the binding rule will not importantly influence the
performance.
The performance investigations and calculations of the
βγ -optimal futility boundaries in “Clinical trial exam-
ple and simulation design” section were done within the
context of a composite endpoint and one relevant main
component which refers to a situation of two correlated
endpoints. We considered only deviations from the origi-
nal planning assumptions in the main component, which
is motivated by the fact that every event in the main
component corresponds to an event in the composite
endpoint. Similar investigations could be made for devi-
ations in the other endpoint or simultaneous deviations
in both endpoints. Generally, our proposed designs could
equivalently be applied to endpoints with other, poten-
tially differing, scale levels. In particular, it would also be
of interest to consider the performance properties of our
designs for uncorrelated endpoints. A systematic inves-
tigation of all possible sequential designs and endpoint
settings within the current work was not feasible. There-
fore, we encourage to perform further simulations in order
to determine a suitable two-stage design for the specific
situation at hand. Further, in this work we chose the
Pocock approach for the local significance levels, which
facilitates stopping the study early at the interim analysis.
Allowing decision criteria that are more conservative in
stopping at the interim analysis as, for example, proposed
by O’Brien and Fleming [2] will improve the overall power.
The general principles of optimal futility boundaries
might be transferred similarly to group-sequential designs
with more than two stages or patient-wise interim looks
as long as the number of interim looks is fixed in advance.
The implementation of our ideas in these situations will
be the task of future work.
Conclusion
In this paper, we presented general optimality crite-
ria for the choice of suitable futility boundaries which
maximize the probability of detecting small or opposite
treatment effect while limiting the power loss and the
probability of stopping the study ‘wrongly’. We illustrated
the criteria on three different group sequential designs
including two endpoints, which are motivated by the
fact that in many clinical trial applications it is not suf-
ficient to consider only one primary endpoint in order
to adequately describe the efficacy of a new treatment.
As the properties of futility boundaries are often not con-
sidered in practice and unfavorably chosen futility bound-
aries may have serious consequences with respect to the
performance of the study design, we recommend assessing
the impact of these boundaries according to the proposed
admissibility and optimality criteria.
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